Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 3/20 | 0.37 |
| ▸ | KRAS | P01116 | 5/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20045937 | 0.85 | USP30 (0.41) | USP30HSD17B3BTKKRAS | |
| SCHEMBL20132916 | 0.84 | USP30 (0.43) | USP30HSD17B3BTKKRAS | |
| SCHEMBL20132843 | 0.83 | BTK (0.40) | BTKESR2 | |
| SCHEMBL20132849 | 0.83 | ACHE (0.42) | BTKKRASKDM5AMGLL | |
| SCHEMBL20045467 | 0.82 | KDM5A (0.37) | BTKKRASKDM5AMGLL | |
| SCHEMBL20046512 | 0.80 | KDM5A (0.35) | BTKKRASKDM5AMGLLMAP3K5 | |
| SCHEMBL20045414 | 0.79 | JAK3 (0.45) | BTK | |
| SCHEMBL20045486 | 0.79 | KRAS (0.39) | KRASMGLL | |
| SCHEMBL20132862 | 0.79 | KDM4E (0.38) | BTKKRASMGLL | |
| SCHEMBL20045939 | 0.78 | BTK (0.36) | BTKKRASMGLLMAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-05-10 | — | — | US | disclosed |
| WO-2018068017-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | KRAS, NRAS, HRAS | USP30 1696/4885HSD17B3 4246/4885BTK 758/4885 |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | USP30 1574/4885HSD17B3 4240/4885BTK 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.